Format
Items per page
Sort by

Send to:

Choose Destination

Results: 9

1.

Influenza virus PB1 and neuraminidase gene segments can cosegregate during vaccine reassortment driven by interactions in the PB1 coding region.

Cobbin JC, Ong C, Verity E, Gilbertson BP, Rockman SP, Brown LE.

J Virol. 2014 Aug;88(16):8971-80. doi: 10.1128/JVI.01022-14. Epub 2014 May 28.

2.

The source of the PB1 gene in influenza vaccine reassortants selectively alters the hemagglutinin content of the resulting seed virus.

Cobbin JC, Verity EE, Gilbertson BP, Rockman SP, Brown LE.

J Virol. 2013 May;87(10):5577-85. doi: 10.1128/JVI.02856-12. Epub 2013 Mar 6.

3.

Development of an enzyme-linked immunoassay for the quantitation of influenza haemagglutinin: an alternative method to single radial immunodiffusion.

Bodle J, Verity EE, Ong C, Vandenberg K, Shaw R, Barr IG, Rockman S.

Influenza Other Respir Viruses. 2013 Mar;7(2):191-200. doi: 10.1111/j.1750-2659.2012.00375.x. Epub 2012 May 15.

PMID:
22583601
4.

Abortive replication of influenza virus in mouse dendritic cells.

Ioannidis LJ, Verity EE, Crawford S, Rockman SP, Brown LE.

J Virol. 2012 May;86(10):5922-5. doi: 10.1128/JVI.07060-11. Epub 2012 Mar 14.

5.

Rapid generation of pandemic influenza virus vaccine candidate strains using synthetic DNA.

Verity EE, Camuglia S, Agius CT, Ong C, Shaw R, Barr I, Middleton D, Rockman S.

Influenza Other Respir Viruses. 2012 Mar;6(2):101-9. doi: 10.1111/j.1750-2659.2011.00273.x. Epub 2011 Jul 19.

PMID:
21771285
6.

The development of vaccine viruses against pandemic A(H1N1) influenza.

Robertson JS, Nicolson C, Harvey R, Johnson R, Major D, Guilfoyle K, Roseby S, Newman R, Collin R, Wallis C, Engelhardt OG, Wood JM, Le J, Manojkumar R, Pokorny BA, Silverman J, Devis R, Bucher D, Verity E, Agius C, Camuglia S, Ong C, Rockman S, Curtis A, Schoofs P, Zoueva O, Xie H, Li X, Lin Z, Ye Z, Chen LM, O'Neill E, Balish A, Lipatov AS, Guo Z, Isakova I, Davis CT, Rivailler P, Gustin KM, Belser JA, Maines TR, Tumpey TM, Xu X, Katz JM, Klimov A, Cox NJ, Donis RO.

Vaccine. 2011 Feb 17;29(9):1836-43. doi: 10.1016/j.vaccine.2010.12.044. Epub 2011 Jan 1.

PMID:
21199698
7.

Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo.

Gorry PR, McPhee DA, Verity E, Dyer WB, Wesselingh SL, Learmont J, Sullivan JS, Roche M, Zaunders JJ, Gabuzda D, Crowe SM, Mills J, Lewin SR, Brew BJ, Cunningham AL, Churchill MJ.

Retrovirology. 2007 Sep 23;4:66.

8.

Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions.

Verity EE, Zotos D, Wilson K, Chatfield C, Lawson VA, Dwyer DE, Cunningham A, Learmont J, Dyer W, Sullivan J, Churchill M, Wesselingh SL, Gabuzda D, Gorry PR, McPhee DA.

J Virol. 2007 Sep;81(17):9268-78. Epub 2007 Jun 13.

9.

Broad neutralization and complement-mediated lysis of HIV-1 by PEHRG214, a novel caprine anti-HIV-1 polyclonal antibody.

Verity EE, Williams LA, Haddad DN, Choy V, O'Loughlin C, Chatfield C, Saksena NK, Cunningham A, Gelder F, McPhee DA.

AIDS. 2006 Feb 28;20(4):505-15. Erratum in: AIDS. 2006 Apr 24;20(7):1093-4.

PMID:
16470114
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk